Multiple Myeloma

>

Latest News

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.
Novel Allogenic CAR T Therapy Shows Responses in R/R Multiple Myeloma

October 12th 2024

P-BCMA-ALLO1 yielded lymphodepletion responses even among those with prior exposure to other CAR T-cell therapies or bispecific agents.

Data support the addition of daratumumab to standard lenalidomide maintenance in patients with newly diagnosed multiple myeloma following transplant.
Post-Transplant Daratumumab Combo Increases MRD Negativity in NDMM

October 9th 2024

Treatment with durcabtagene autoleucel meets the primary end point of a phase 2 study in relapsed/refractory multiple myeloma.
Durcabtagene Autoleucel Yields Responses in Relapsed/Refractory Myeloma

October 7th 2024

Data from a phase 1b/2 trial show that sonrotoclax/dexamethasone appears to be well tolerated in a heavily pretreated multiple myeloma population.
Novel BCL-2 Inhibitor Combo Shows Enduring Responses in R/R Myeloma Subtype

October 5th 2024

Thomas G. Martin, MD, discussed the advantages of quadruplet therapy for multiple myeloma in light of an FDA approval for Isa-VRd in this indication.
Quadruplet Therapy Shows Benefit for Newly Diagnosed Multiple Myeloma

October 4th 2024